louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06212921: Biomarkers in Prediction of AMI
Official title: Biomarkers In Prediction of Acute Mesenteric Ischaemia: a Prospective Multicentre Study (BIPAMI Study)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acute Mesenteric Ischemia
Lead sponsor: University of Tartu
Sponsor class: OTHER
First posted: 2024-01-19
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Sequential blood samples will be collected from study subjects
Primary purpose: DIAGNOSTIC

Brief summary: Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Different combinations of biomarkers for different sub-types and severity of AMI, and different time points of measurement after onset of symptoms.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Initial decision in favour of further diagnostics of mesenteric ischaemia

Exclusion Criteria:

* Age \<18 years
* Consent declined by patient or next of kin (delayed consent)
* Chronic mesenteric ischaemia without an acute event
* Immediate decision for withdrawal of further diagnostics and active treatment
* Referral from another hospital with already established diagnosis of AMI
* AMI diagnosed at surgery without previously having been considered

Primary outcomes:
measure: Rate of correctly predicted cases of acute mesenteric ischaemia
timeFrame: 10 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tartu
country: Estonia
facility: Tartu University Hospital
city: Luzern
country: Switzerland
facility: Lucerne Cantonal Hospital
Study officials:
References:
Clinical trial NCT00671021: Duration of Platelet Inhibition by Aspirin
Official title: Evaluation of Duration of Platelet Inhibition by Aspirin in a Standard 24-hour Interval Dosing Regimen
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: platelet aggregation
aspirin
Lead sponsor: Hopital du Sacre-Coeur de Montreal
Sponsor class: OTHER
First posted: 2008-05-02
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients suffering from stable CAD, on chronic ASA therapy

Brief summary: The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death. However, not all patients benefit of aspirin administration to the same extent, thus high-lighting a sub-population of patients with inadequate platelet response to ASA. The mechanisms underlying reduced ASA efficacy remain elusive. A recent report has suggested that platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase enzyme, once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients.

The current study aims to evaluate, in patients suffering from stable coronary artery disease, the stability of platelet inhibition by aspirin during the normal once daily dosing regimen.


Eligibility criteria: Inclusion Criteria:

* Patients suffering from stable CAD, on chronic ASA therapy
* Patients willing to participate in the study and to sign the informed consent form

Exclusion Criteria:

* Acute coronary syndrome or revascularization in the last 3 months prior to enrolment
* Concurrent ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), clopidogrel, ticlopidine, dipyridamole, warfarin or acenocoumarol
* Frequent use (more than once a week) of non-prescription NSAIDs or drugs containing ASA in the 10 days preceding enrolment
* Major surgical procedure within 1 month before enrolment
* Hemorrhagic diathesis or known platelet dysfunction
* Platelet count outside the 100 to 450 x109/L range for technical reasons
* Hematocrit \< 25% or haemoglobin \< 100 g/L
* Patient undergoing dialysis for chronic renal failure
* Patient found to be ASA resistant

Primary outcomes:
measure: Platelet aggregation TxA2 formation
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Hôpital du Sacré-Coeur de Montréal
state: Quebec
Study officials:
affiliation: Hopital du Sacre-Coeur de Montreal
name: Jean G Diodati, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00323921: Determination of Safety and Efficacy of a Laser With Cooling for Treatment of Skin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aged Skin
Lead sponsor: Candela Corporation
Sponsor class: INDUSTRY
First posted: 2006-05-10
Enrollment: 36
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The appearance of aged skin is a common cosmetic complaint of middle aged and older individuals. This study evaluates the safety and efficacy of a new laser with cooling to improve the appearance of aged skin. The laser being used will heat various depths of the skin while protecting the outer layer.


Eligibility criteria: Inclusion:

Aged skin, light to medium skin types.

Exclusion:

Known photosensitivity Any of the following pre-existing skin conditions: eczema, psoriasis, allergic dermatitis or other conditions that may affect treatment.

Other treatments within the past year for aged facial skin

Primary outcomes:
measure: score on a grading scale at post treatment visits
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: United States Naval Medical Center, San Diego
name: E. V. Ross, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06493721: Clear Aligner Treatment With and Without Low Level Laser Therapy for Upper Incisor Crowding
Official title: Clear Aligner Treatment for Upper Incisor Crowding With Low-Level Laser Therapy: A Comparative Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Crowding of Anterior Maxillary Teeth
Keywords: Clear aligner treatment
Low level laser therapy
Clear aligner therapy
Accelerated orthodontics
orthodontic tooth movement
upper incisor crowding
orthodontic pain
Lead sponsor: Faculty of Dental Medicine for Girls
Sponsor class: OTHER_GOV
First posted: 2024-07-10
Enrollment: 22
Sex: ALL
Minimum age (years): 16
Maximum age (years): 23
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to assess the effect of Low Level Laser Therapy (LLLT) on Upper Incisor Crowding using Clear Aligner Treatment (CAT).

Detailed description: The goal of this clinical trial is to assess the effect of Low Level Laser Therapy (LLLT) on Upper Incisor Crowding using Clear Aligner Treatment (CAT) on healthy patients (16-23 years old) with complete set of dentition and Angle class I. The main questions to answer are:

1. Evaluate rate of Upper Incisor Decrowding using CAT and LLLT
2. Does LLLT affect pain during CAT?

Researchers will compare CAT with LLLT to CAT without LLLT to see if the LLLT will accelerate Orthodontic Tooth Movement.

Participants will:

* Change to a new aligner every 7 days.
* Visit the clinic every week for checkup.
* Log in pain scores every 6, 24, 48 and 72 hours after delivery of new aligners.

Eligibility criteria: Inclusion Criteria:

1. Patients age ranging from 16-23 years old with Angle class I malocclusion and upper anterior crowding.
2. Healthy, compliant and internally motivated patient.
3. Full set of maxillary permanent dentition except third molar.

Exclusion Criteria:

1. Previous orthodontic treatment.
2. Any systemic diseases that could interfere with orthodontic treatment.
3. Gross gingival or periodontal problems

Primary outcomes:
measure: Rate of tooth movement
timeFrame: Initial alignment at the end of 3rd month during treatment planning of clear aligner
Secondary outcomes:
measure: Pain level
timeFrame: Initial alignment at the end of 3rd month phase during treatment planning of clear aligner
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dental Medicine for Girls Al-Azhar University
Study officials:
affiliation: Faculty of Dental Medicine, Girls Branch, Al Azhar University
name: Samir Abdo
role: STUDY_DIRECTOR
References:
Clinical trial NCT00258921: RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
Official title: An International Registry in Essential Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2005-11-28
Enrollment: 31870
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: To support physicians in their active management of hypertensive patients. By targeting specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor the BP values and as such will have an individualized control of the treatment in each patient.


Eligibility criteria: The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Main criteria are listed hereafter:

Inclusion Criteria:

* Adult hypertensive
* Either newly diagnosed and untreated
* or previously treated and uncontrolled Patients of both sexes with essential hypertension

Exclusion Criteria:

* Known secondary hypertension
* Known secondary curable hypertension (i.e. pheochromocytoma, aldosterone producing adenoma, Cushing disease). Patients with renal disease are not excluded.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Sanofi
name: Pascale BLONDIN, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02803021: Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay, UVA Protection Factor Assay (UVAPF), Minimal Persistent Pigment- Darkening Dose (MPPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agent
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-06-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF(Self History Form)
* Signed and dated Informed Consent Form
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) Form
* An unbAmbiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnosed by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02853721: Early Prediction of Hypocalcaemia Following Thyroid Surgery
Official title: Early Prediction of Hypocalcaemia Following Thyroid Surgery: A Prospective Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypocalcemia
Lead sponsor: University of Cagliari
Sponsor class: OTHER
First posted: 2016-08-03
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: 150 patients divided into two groups.The experimental group was submitted at the assay of iPTH six hours after surgery whilst the control group was submitted to a daily assay of serum calcium and phosphorus.

Detailed description: Purpose: The aim of this randomized controlled trial was to validate the results of a previous prospective cohort study conducted in the same surgical unit regarding the use of concomitant intact parathyroid hormone (iPTH) and serum calcium measurement in predicting hypocalcemia after total thyroidectomy.

Methods: From January 2014 to January 2015, 150 patients underwent total thyroidectomy in our department and were divided into two groups. The experimental group was submitted at the assay of iPTH six hours after surgery whilst the control group was submitted to a daily assay of serum calcium and phosphorus. Sensitivity and specificity of different serum measurements have been calculated using the Receiver-operator characteristics (ROC) curve.

Eligibility criteria: Inclusion Criteria:

* Be submitted to total thyroidectomy during the study period
* Have signed the informed consent

Exclusion Criteria:

* Lack of inclusion criteria
* Lobectomy with isthmusectomy or partial or subtotal thyroidectomy
* Completion thyroidectomy
* Concomitant hyperparathyroidism was present
* Concomitant treatment with oral calcium and/or vitamin D prior to surgery

Primary outcomes:
measure: Sensibility and specificity of iPTH and serum calcium measurement
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03550521: Interrupting Self-Harm Study
Official title: A Mixed Methods Investigation of Brief Mindfulness Training and Self-injury Attentional Bias Among Self-injuring Adolescents
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Nonsuicidal Self-injury
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2018-06-08
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: My study will employ a convergent mixed methods two-arm parallel randomized controlled design. The qualitative strand will primarily rely on semi-structured interview procedures to answer the following questions: (1) How do adolescents perceive and experience the phenomenon of nonsuicidal self-injury (NSSI)? (2) What do adolescents believe needs to be done to address NSSI? The quantitative strand will primarily rely on clinical interview data, self-report measures, and an experimental task protocol to answer the following question: What is the impact of a brief mindfulness induction (versus a control condition) on self-injury attentional bias among self-injuring adolescents?


Eligibility criteria: Inclusion Criteria:

* To be included in the study, a participant must be: 1) at least 12 years old and no more than 18 years old, 2) able to understand and communicate in English, 3) willing and able to participate in all study procedures, and 4) currently engaging in nonsuicidal self-injury OR have a history of nonsuicidal self-injury.

Exclusion Criteria:

* Individuals will be excluded from the study if they are experiencing a suicidal crisis at the time of the study procedures (e.g., they endorse suicidal ideation, planning, and intent as determined by the Mini International Neuropsychiatric Interview 7.0) and require crisis intervention or hospitalization.

Primary outcomes:
measure: Change in self-injury attentional bias as measured by a Dot Probe Paradigm
timeFrame: The Dot Probe Paradigm will be administered immediately preceding the mindfulness or control conditions and immediately following the mindfulness or control conditions
Secondary outcomes:
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
affiliation: University of Utah College of Social Work
name: Michael R Riquino, MSW
role: PRINCIPAL_INVESTIGATOR
References:
citation: Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Interventions for self-harm in children and adolescents. Cochrane Database Syst Rev. 2021 Mar 7;3(3):CD013667. doi: 10.1002/14651858.CD013667.pub2.
Clinical trial NCT00638521: Immune-cell Membrane Trafficking
Official title: Trauma and Sepsis Induced Changes in Immune-cell Membrane Receptor Trafficking
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Severe Trauma
Keywords: lipids
proteins
membrane
lipid raft
Lead sponsor: University of Washington
Sponsor class: OTHER
Collaborators: name: National Institute of General Medical Sciences (NIGMS)
First posted: 2008-03-19
Enrollment: 213
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Inclusion criteria:

Brief summary: Organ failure following trauma is a leading cause of morbidity and mortality. It appears that the development of organ failure is a direct result of an altered immune response. This altered response results in the production of circulating factors in the blood that causes direct injury to the injured patients' organs. The mechanism in which this altered immune response occurs is unknown. Based on work we have performed in our laboratory, we believe that this response is initiated on the cell membrane of particular immune cells known as macrophages. Although the cell membrane may appear uniform, it is not. The membrane is composed of specific segments that allow proteins to associate with each other forming receptors that are required for immune cell activation. These specific membrane components are composed of various lipids and cholesterol, and have been termed lipid rafts. Based on our laboratory work it appears that these lipid rafts can be altered following injury. In particular both the lipid and protein content within these raft segments may be altered allowing immune cells to become active leading to the production of factors that directly injure normal cells and organs. Thus, we plan to examine if these laboratory findings can be seen in patients suffering from trauma who develop clinical organ failure at Harborview Medical Center. If this is accomplished, this data will lead to the development of both prognostic and therapeutic interventions for the optimal care of injured patient


Eligibility criteria: Inclusion Criteria:

* age 18 years or older, blunt or penetrating trauma and
* one or more of the following: systolic blood pressure less than 90 mmHg at the scene or within one hour of arrival to the Emergency Department, 2) base deficit ≥ -6 within one hour of admission, 3) ISS greater than 25, or 4) more than 6 units of blood transfused in the first 12 hours.-

Exclusion Criteria:

Primary outcomes:
measure: Assessment of protein and lipid changes in immune cells following severe injury
timeFrame: 5/08 to 8/12
Secondary outcomes:
measure: Assessment of severe injury effect on plasma and cellular lipid content
timeFrame: 5/08 to 8/12
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Harborview Medical Center
state: Washington
Study officials:
affiliation: University of Washington
name: Joseph Cuschieri, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04314921: 10-week Yoga Practice Effect on Cognitive and Motor Function in Older Adults
Official title: 10-week Yoga Practice Effect in Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Healthy Aging
Lead sponsor: Lithuanian Sports University
Sponsor class: OTHER
First posted: 2020-03-19
Enrollment: 33
Sex: ALL
Minimum age (years): 60
Maximum age (years): 76
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Thirty-three healthy elderly people, who were classified into two age groups, participated in this study. All participants had not practiced yoga before and were asked not to perform any sports activities while the research was ongoing. In the experimental group, participants (n = 18) had to participate in 10 weeks of yoga classes. In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life.

Experimental measurements: Brunel, PSS-14 and HAD questionnaires


Eligibility criteria: Inclusion Criteria:

* age, from 60 years old
* a statement by a local family physician about general good physical health
* never tired to practice yoga before

Exclusion Criteria:

* cardiovascular diseases
* musculoskeletal system diseases (osteoporosis, osteochondrosis, hernias)
* neurodegenerative diseases
* oncological diseases
* glaucoma
* injuries and surgeries in last 3 years

Primary outcomes:
measure: Brunel mood scale (BRUMS)
timeFrame: 10 weeks
measure: Hospital anxiety and depression scale (HADS)
timeFrame: 10 weeks
measure: Perceived stress scale -14
timeFrame: 10 weeks
measure: Human Free BDNF
timeFrame: 10 weeks
measure: Measurement of cognitive functions
timeFrame: 10 weeks
measure: Psychomotor function evaluation
timeFrame: 10 weeks
measure: Heart rate variability
timeFrame: 10 weeks
measure: Balance procedure
timeFrame: 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kaunas
country: Lithuania
facility: Lithuanian Sports Unviersity
Study officials:
References: